4,200 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Bought by Entropy Technologies LP

Entropy Technologies LP purchased a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 4,200 shares of the medical research company's stock, valued at approximately $1,405,000.

Other large investors have also recently bought and sold shares of the company. Capital Advisors Ltd. LLC grew its holdings in shares of Bio-Rad Laboratories by 193.8% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company's stock worth $26,000 after purchasing an additional 62 shares in the last quarter. UMB Bank n.a. grew its stake in Bio-Rad Laboratories by 140.6% during the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company's stock worth $26,000 after buying an additional 45 shares in the last quarter. EntryPoint Capital LLC bought a new position in Bio-Rad Laboratories in the 1st quarter valued at about $51,000. Headlands Technologies LLC acquired a new position in shares of Bio-Rad Laboratories in the 2nd quarter valued at approximately $51,000. Finally, Quarry LP bought a new stake in shares of Bio-Rad Laboratories during the 2nd quarter worth approximately $59,000. 65.24% of the stock is owned by institutional investors.

Insider Activity

In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of the firm's stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the transaction, the executive vice president now directly owns 147 shares of the company's stock, valued at approximately $48,582.03. This trade represents a 80.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Andrew J. Last sold 3,000 shares of Bio-Rad Laboratories stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the transaction, the chief operating officer now owns 7,559 shares of the company's stock, valued at $2,494,016.46. This represents a 28.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.06% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages have commented on BIO. Citigroup boosted their price objective on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Wells Fargo & Company initiated coverage on Bio-Rad Laboratories in a research note on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 price target on the stock. Royal Bank of Canada upped their price objective on Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. Finally, StockNews.com upgraded Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, November 1st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, Bio-Rad Laboratories presently has an average rating of "Moderate Buy" and an average target price of $391.80.

Bio-Rad Laboratories Trading Down 3.6 %

Shares of BIO stock traded down $12.97 during trading hours on Thursday, hitting $350.23. 148,088 shares of the company's stock traded hands, compared to its average volume of 246,016. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16. Bio-Rad Laboratories, Inc. has a 12 month low of $262.12 and a 12 month high of $387.99. The stock has a market cap of $9.81 billion, a PE ratio of -12.81 and a beta of 0.93. The stock's 50 day simple moving average is $340.67 and its 200 day simple moving average is $313.77.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The firm had revenue of $649.70 million during the quarter, compared to analyst estimates of $628.18 million. During the same quarter last year, the business earned $2.33 EPS. The company's revenue was up 2.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 9.93 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.